^
    Back
    Association details:
    Biomarker:ERCC1 expression
    Cancer:Malignant Pleural Mesothelioma
    Regimen: (cisplatin + gemcitabine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    BMC Cancer
    Title:

    RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

    Published date:
    08/05/2021
    Excerpt:
    ERCC1 and RRM1 are useful biomarkers that predict better survival outcomes in patients with advanced MPM treated with continuous infusion of gemcitabine plus cisplatin.
    DOI:
    10.1186/s12885-021-08287-5